Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 15 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
- 15 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 15 Feb 2017 Status changed from not yet recruiting to recruiting.